Bioscan Inc.

Bioscan Inc. specializes in advanced diagnostic solutions that non-invasively identify hidden illnesses related to the autonomic nervous system and vascular health, enhancing patient care for healthcare providers worldwide. Bioscan Inc. was founded in 1980 and is headquartered in Washington, US.

The company focuses on non-invasive diagnostic technologies and has undergone strategic changes to optimize its operations. In September 2013, Bioscan was acquired by TriFoil Imaging, with undisclosed financial terms. The founder's background is not available, and there are no mentions of subsidiaries or prior founding experiences. Bioscan's flagship product, the VitalScan ANS System, offers comprehensive testing of autonomic function in about 15 minutes, detecting conditions such as diabetic neuropathy and cardiac autonomic neuropathy.

Another product, the SudoCheck system, examines sweat gland function to assess nerve integrity, particularly useful for diabetes patients. Their primary clients include general practitioners, cardiologists, neurologists, and pain management specialists, primarily in North America and Europe, enhancing patient care through advanced diagnostic capabilities. The revenue model for Bioscan centers around direct sales of their diagnostic systems like the VitalScan ANS System and SudoCheck to healthcare providers. Revenue streams include one-time purchases and potential ongoing revenues from service agreements and maintenance contracts, contributing to the critical diagnostic capabilities essential for effective patient management.

Bioscan Inc. is likely to leverage its recent funding round of USD 750,000 from the VENTURE DEBT round to develop new products and expand into new markets. The strategic focus includes enhancing the capabilities of existing products and potentially diversifying their offerings, although specific product launch dates are not disclosed. The acquisition by TriFoil Imaging may also facilitate broader market access and operational synergies to support further growth initiatives.